CLSDQ
Clearside Biomedical, Inc.Company Information
- Company Name
- Clearside Biomedical, Inc.
- CIK
- CIK0001539029
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CLSDQ: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CLSDQ
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-02-24
- Last sale
- 2024-01-19
- Shares purchased (TTM)
- 206,103
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 27,136
- Shares outstanding
- 5,233,981
- Ownership
- 0.52%
Earnings Market Reaction
- Filing date
- 2025-11-14
- Price on filing date
- —
- 1-month reaction
- -79.32%
- 3-month reaction
- -80.37%
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 7 | 9 | 14 | 20 | 14 | 18 | 35 | 29 | 29 | 35 | 41 | 48 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 8 | 12 | 16 | 21 | 25 | 30 | 36 | 30 | 31 | 36 | 43 | 49 | ||||||
| Short Term Investments | - | - | - | - | 10 | 11 | - | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 0 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | - | 0 | ||||||
| Prepaid Expense Current | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Assets | 12 | 15 | 20 | 25 | 29 | 34 | 40 | 34 | 34 | 39 | 45 | 51 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 1 | ||||||
| Accrued Liabilities Current | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 4 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 3 | 3 | 5 | 5 | 6 | 6 | 6 | 7 | 6 | 5 | 5 | 6 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Revenue Current | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Liabilities Noncurrent | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | ||||||
| Liabilities | 66 | 64 | 66 | 64 | 64 | 62 | 62 | 50 | 47 | 44 | 42 | 41 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 320 | 319 | 318 | 316 | 313 | 312 | 311 | 305 | 303 | 302 | 300 | 299 | ||||||
| Stockholders Equity | -54 | -49 | -46 | -39 | -35 | -28 | -22 | -16 | -13 | -5 | 3 | 11 | ||||||
| Retained Earnings Accumulated Deficit | -374 | -368 | -363 | -355 | -348 | -340 | -333 | -321 | -316 | -307 | -298 | -288 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | 0 | -0 | - | - | - | - | - | - | ||||||
| Liabilities And Stockholders Equity | 12 | 15 | 20 | 25 | 29 | 34 | 40 | 34 | 34 | 39 | 45 | 51 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 27 | 400 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | ||||||
| Shares Outstanding | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialClearside Biomedical, Inc. (CLSDQ) — SEC Financial Statements & Analysis
Clearside Biomedical, Inc. (CLSDQ) is a pharmaceutical preparations company, incorporated in DE. Clearside Biomedical, Inc. trades on OTC as: CLSDQ. Clearside Biomedical, Inc. (CLSDQ)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14. Based on that filing, On profitability, Clearside Biomedical, Inc. posts an operating margin of -689.76%, a net margin of -780.93%, a Return on Equity (ROE) of 58.59%, and a Return on Assets (ROA) of -127.43%. Per share, it reports EPS of $-4.97, diluted EPS of $-4.97, free cash flow per share of $-4.15, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -56.78% year-over-year, net income growth of -18.45% year-over-year, and EPS growth of -22.36% year-over-year. On the balance sheet, it maintains a current ratio of 2.98x, a quick ratio of 2.55x, working capital of $5.48M, a debt-to-equity ratio of -1.22x, a debt ratio of 5.63, free cash flow of $-21.75M (TTM), and net debt of $-6.80M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-4.97
- ROE TTM
- 58.59%
- ROA TTM
- -127.43%
- Debt To Equity
- -1.22x
- Free Cash Flow TTM
- $-21.75M
- Net Revenue TTM Growth 1Y
- -56.78%
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Clearside Biomedical, Inc. in?
Clearside Biomedical, Inc. (CLSDQ) operates in the Pharmaceutical Preparations industry.
What exchange does CLSDQ trade on?
Clearside Biomedical, Inc. (CLSDQ) trades on the OTC.
Where is Clearside Biomedical, Inc. incorporated?
Clearside Biomedical, Inc. is incorporated in DE.
When was Clearside Biomedical, Inc. (CLSDQ)'s most recent SEC filing?
Clearside Biomedical, Inc. (CLSDQ)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14.
What is CLSDQ's EPS (earnings per share)?
Clearside Biomedical, Inc. (CLSDQ)'s trailing twelve month EPS is $-4.97 as of 2025-09-30.
What is CLSDQ's ROE (return on equity)?
Clearside Biomedical, Inc. (CLSDQ)'s trailing twelve month Return on Equity (ROE) is 58.59% as of 2025-09-30.
What is CLSDQ's ROA (return on assets)?
Clearside Biomedical, Inc. (CLSDQ)'s trailing twelve month Return on Assets (ROA) is -127.43% as of 2025-09-30.